GAA-4OH: In Vitro and In Vivo Data for a Novel MASLD Therapeutic Candidate

GAA-4OH is a newly identified nanomolar-potency inhibitor of the enzyme dihydroceramide desaturase-1 (DEGS1). The dataset, shared by Karla Cevallos on figshare in May 2026, likely contains results from screening, kinetic assays, molecular docking, and in vivo mouse model studies. These data support the compound's efficacy in reducing ceramide ratios and improving liver pathology in a model of metabolic dysfunction-associated steatotic liver disease (MASLD).

Use Cases

• Benchmarking novel DEGS1 inhibitor potency based on reported nanomolar activity against fenretinide.
• Validating molecular docking simulations based on the described iminoquinone covalent binding mechanism.
• Correlating ceramide-to-dihydroceramide ratios with histopathological outcomes based on described improvements in steatosis, inflammation, and fibrosis.
• Assessing therapeutic safety profiles based on the reported absence of body weight loss and toxicity signs in the mouse model.

Strengths

• Data is associated with a specific, potent inhibitor (GAA-4OH) with nanomolar activity.
• Findings are supported by multiple experimental approaches, including in vitro screening, kinetic assays, docking, and an in vivo mouse model.
• The dataset is openly shared under a CC-BY-NC-4.0 license, permitting non-commercial reuse with attribution.

Limitations

• The dataset is very small at 1.9 KB, indicating limited scope, likely summary results rather than raw experimental data.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for statistical analysis.

Provenance

Source

figshare, author Karla Cevallos.

Collection Method

Likely generated from laboratory experiments involving chemical screening, enzyme assays, computational docking, and animal model studies.

Freshness

Last updated 2026-05-04 11:41:32; freshness should be verified.